Ert Batten Brineura denied as non-formulary by Cigna?

Cigna's specific coverage criteria for ert batten brineura are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Brineura as Non-Formulary — and Why That Denial Is Challengeable

Brineura (cerliponase alfa) is an ultra-orphan biologic for CLN2 Batten disease. Because it treats an exceptionally rare condition, it is often placed in a restricted tier or excluded from Cigna's standard formulary. A non-formulary denial does not mean the drug is clinically inappropriate — it means Cigna's pharmacy and therapeutics committee has not placed it in an auto-covered tier. For rare diseases with no therapeutic alternatives, non-formulary status is routinely overcome through a formulary exception or medical-necessity appeal.

## Federal Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you have the right to appeal any coverage denial, including non-formulary determinations. A non-formulary denial is effectively a coverage exclusion being applied to a specific drug — it can be reviewed on the grounds that (a) no formulary alternative is clinically appropriate, and (b) failure to cover the only FDA-approved therapy for this condition is an arbitrary restriction. If the patient's condition is deteriorating, request expedited review at every level. External review through an Independent Review Organization (IRO) is available after internal exhaustion, generally within a 4-month window from the original denial date.

## Appeal Process and Timeline

1. Formulary exception request — the first and fastest path. Submit through Cigna's pharmacy benefit channel with a prescriber letter explaining why no formulary alternative is adequate (or exists). 2. Internal appeal — if the exception is denied, file a formal internal appeal. Request all clinical criteria Cigna applied and respond to each point. 3. External review — after internal exhaustion, request IRO review. For a pediatric patient with a progressive fatal disease and no alternative therapy, external reviewers frequently overturn non-formulary exclusions.

## Documentation to Gather

• Confirmed CLN2 diagnosis: genetic and enzymatic laboratory reports.
• No adequate alternative: a prescriber letter explicitly stating that no Cigna-formulary drug treats CLN2 Batten disease, referencing the FDA-approved indication language from the Brineura prescribing label.
• Disease severity and progression data: neurologist assessments showing current functional status and rate of decline.
• Prescriber medical-necessity letter: directly addressing the formulary-exception criteria listed in Cigna's pharmacy benefit policy.

## Criteria-Mapping Structure

Obtain Cigna's formulary exception criteria from your Explanation of Benefits (EOB) and from Cigna's published formulary exception policy. Obtain the FDA-approved indication from the Brineura prescribing label. Map each exception criterion to specific chart facts. The central argument is straightforward: there is no formulary alternative for this indication, making a formulary exclusion functionally equivalent to a denial of the only medically available therapy.